Objectives: This study was designed to verify the antiangiogenic activity of ferulic acid (FA) and its potency to inhibit cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) expression in the chorioallantoic membrane (CAM) model. Moreover, we verified its mechanism of action by docking the molecule on COX-2, tyrosine kinase, and VEGF-2 proteins in silico. Materials and Methods: An antiangiogenesis assay of FA at doses of 30, 60, and 90 mu g was performed using the CAM of chicken eggs that were 9 days old and stimulated by 60 ng of basic fibroblast growth factor. Celecoxib (60 mu g) was used as the reference drug. The inhibitory activity on VEGF and COX-2 expression was determined by immunohistochemistry assay. Molecular docking of FA was accomplished by Molegro Virtual Docker program ver. 5.5 on COX-2 enzyme (PDB ID 1CX2), tyrosine kinase receptor (PDB ID 1XKK), and VEGF-2 receptor (PDB ID 4ASD). Results: FA at doses of 30, 60, and 90 mu g significantly prevented angiogenesis in the CAM model, which was represented as inhibitory activity against endothelial cells of blood vessels (42.6-70.7%) and neovascularization (43.0-86.6%). The inhibitory activity of FA against VEGF expression was stronger than its action on COX-2 expression. Molecular docking on VEGF-2 receptor resulted in an RS value of FA of-73.844 kcal/mol and for celecoxib it was-94.557 kcal/mol. The RS value on tyrosine kinase of FA was-84.954 kcal/mol, while on celecoxib it was-93.163 kcal/mol. Docking on COX-2 receptor gave an RS value of FA of-73.416 kcal/mol, while for celecoxib it was-118.107 kcal/mol. Conclusion: Reductions in VEGF-2 and COX-2 expression due to treatment with FA at the dose range 30-90 mu g appeared to be related to angiogenesis inhibition, which was shown by two parameters, namely inhibition of neovascularization and endothelial cell growth in blood vessels. It was concluded that FA is a promising antiangiogenic therapeutic agent especially at the early stage, and this activity can arise from inhibitory action on COX-2 and VEGF-2
15 January 2024 in Journal of Advanced Pharmaceutical Technology & Research
Luteolin exhibited antibacterial activity against Escherichia coli and its chemical structure similar to that of ciprofloxacin (CPF) which works by inhibiting DNA gyrase. Filtrate from passion fruit extract containing luteolin and its derivatives could inhibit extended-spectrum β-lactamase (ESBL)-producing E. coli. Antibacterial compounds that can also inhibit ESBL will be valuable compounds to overcome the problem of resistant bacteria. This study aimed to ensure the potency of luteolin and luteolin derivatives targeting DNA gyrase and ESBL by in silico approach. Docking simulation of ligands L1-L14 was performed using AutoDock Vina, and pharmacokinetics and toxicity (absorption, distribution, metabolism, excretion, and toxicity) profiles were predicted by pKCSM online. The docking result revealed higher binding affinity on DNA gyrase (PDB.1KZN) of 12 luteolin derivatives (energy <−7.6 kcal/mol) compared to CPF and higher affinity (energy <−6.27 kcal/mol) of all compounds than clavulanic acid against ESBL CTX-M-15 (PDB.4HBU). The compounds could be absorbed through the human intestine moderately, which showed low permeability to blood–brain barrier, nontoxic and nonhepatotoxic. The most active luteolin glycoside (L6) is capable to inhibit DNA gyrase and ESBL from E. coli which provided the potential against resistant bacteria and was promoted as lead compounds to be developed further.
25 June 2021 in Journal of Basic and Clinical Physiology and Pharmacology
Objectives: This study was purposed to design gossypetin derivatives which have higher activity than the parent compound found in Hibiscus sabdariffa and to find the most potent compound as the antibacterial agent. Methods: Twenty-five gossypetin derivatives were designed by conjugation the molecular structure of gossypetin with acyl group from some natural phenolic acids. The antibacterial activity was predicted by docking simulation on Escherischia coli DNA gyrase (PDB. 1KZN) which was performed by Molegro Virtual Docker. Potency as an antibacterial agent was evaluated based on binding affinity, hydrogen bond, and similarity of binding pattern with reference ligand Clorobiocin. Results: Almost all derivatives showed higher binding affinity than gossypetin (docking score −113.43 kcal/mol). The most active compound was 3G19 with docking score −167.42 kcal/mol which was comparable to clorobiocin (docking score −167.75 kcal/mol). The compounds displaying higher activity than gossypetin were belonged to 7,4′-dimethyl and 3,7,4′-trimethylgossypetin of coumaric acid, caffeic acid, and also ferulic acid. The compounds showed similar binding mode with clorobiocin especially in interaction with Asn46. Conclusions: Gossypetin derivatives designed by conjugating the gossypetin with phenolic acyl increased in silico antibacterial activity of the parent compound. The 3,7,4′-trimethylgossypetin of coumaric acid was selected as the most potent compound for antibacterial agents.
The increasing bacterial resistances to antibiotics are serious threat to world health. In Indonesia, there are resistant bacteria such as Methicillin Resistant Staphylococcus aureus (MRSA). In order to overcome the problem, the compounds contained in the Hibiscus sabdariffa L. are potential to be developed as new antibacterial against MRSA. To confirm the antibacterial activity, the extract of roselle calyx was tested against MRSA. The twelve compounds contained in the extract was docked into binding site of PBP2a using Autodock 4.2.6. The results showed MIC 2.5% of roselle extract. Two flavonoid compounds comply the Lipinski’s rules and the docking results showed all compounds had higher binding affinity than reference ligand ceftobiprole. The quantitative structure-physicochemical property relationship (QSPR) found that steric property (CMR) and energy (Etotal) of ligand contributed to the binding affinity against PBP2a. It concluded kaempferol-rutinoside was the most potential compound from H. sabdariffa that could be selected as lead compound to be develop as antibacterial agents.
Background: Acetylsalicylic acid (aspirin), widely used as an antiplatelet agent, is more likely to inhibit COX-1. Along with discovering the cardioprotective role of COX-1 in controlling platelet aggregation, it is important to develop a selective COX-1 inhibitor. Objective: This study aims to design acyl salicylic acid derivatives intended as COX-1 inhibitors. Method: Fourteen derivatives (AcS1-14) were subjected to a quantitative structure-activity relationship (QSAR) study, and 31 QSAR models were obtained using multiple linear regression (MLR) analysis. Molecular docking was performed on COX-1 (PDB. 1PTH) using the Molecular Orbital Environment (MOE) program ver2022.02, and QSPR analysis was conducted to ascertain the contribution of physicochemical descriptors to the free energy score (S) of ligand-receptor complexes. Results: The QSAR-Hansch model predicted hydrophobicity (LogP) and molecular energy (Etotal) and contributed to pain inhibitory action. All derivatives displayed higher in silico affinity than aspirin (S= -4.33±0.00 kcal/mol), and compound AcS7 afforded the highest (S= -5.32 kcal/mol). In QSPR, Etotal also revealed a positive contribution to the affinity. AcS1, AcS2, AcS5, AcS7, and AcS8 expressed higher drug-like properties than aspirin. Conclusion: Derivatives with optimum hydrophobicity and high energy would generate potent COX-1 inhibition. The five selected compounds were recommended to be developed as drug candidates for COX-1 inhibitors.